Now, the excitement is growing about a venture aimed at eliminating the need to send samples through the costly and inefficient, costly and lengthy process of clinical trials by developing gene sequencing that can be done at the point of care. The problem for pharma companies is how to deploy expensive molecular diagnostic tests with relatively narrow diagnostic applications, or "subtle differences," that can now be identified in real time. There is a shortage of qualified laboratory personnel who understand such technologies and how to use them. Sometimes, new technologies are not applied to the right patients. The supply chain involved in shipping samples from one clinical lab to another has yet to be built to facilitate such technology. The cost of clinical trials continues to rise, limiting the scope of clinical research, and biopharma companies are looking for ways to make clinical trials simpler. That is where Provitive Genetics comes in, and if successful, it will ultimately create a logistics environment for pharmaceutical companies and biotechnology companies to improve the way clinical trials are carried.